FDA OKs Drug to Treat Pulmonary Hypertension

Wednesday, 09 Oct 2013 12:19 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

The U.S. Food and Drug Administration said on Tuesday it has approved Bayer AG's drug to treat two types of pulmonary hypertension.
The drug, Adempas, also known as riociguat, is designed to treat thromboembolic pulmonary hypertension, a rare disease typically caused by blood clots that restrict the flow of blood from the heart to the lungs.
It is also designed to treat pulmonary arterial hypertension, in which arteries of the lungs constrict, forcing the heart to work harder. Symptoms of both conditions are similar and include shortness of breath, fatigue, weakness and potential heart failure.
The drug will carry a boxed warning, the most serious possible, against use in pregnant women due to the risk of harming the fetus. All female patients must be enrolled in a risk mitigation program, comply with pregnancy testing and be counseled on the need for contraception.
Prescribers will be required to be certified by enrolling in the program, and pharmacies will only be able to dispense Adempas to patients eligible to receive it under the risk mitigation program.
Adempas belongs to a class of drugs known as soluble guanylate cyclase stimulators that help arteries relax to increase blood flow and decrease blood pressure. It is designed to improve the ability of patients to exercise.
The FDA had initially suggested the drug be approved at doses lower than the maximum 2.5 milligram dose proposed by Bayer, arguing that a starting dose of 0.5 milligram and maximum dose of 1.5 milligrams three times a day would confer the same benefit as the higher dose with a reduced risk of side effects, particularly low blood pressure.
But a panel of outside advisors to the FDA disagreed and recommended approving the drug with a 2.5-milligram limit, saying they wanted as many options as possible and that decisions on dosing should be left to physicians. In approving the drug, the FDA did not restrict the maximum dose to 1.5 milligrams.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

American Ebola Survivor: 'God Saved My Life'

Thursday, 21 Aug 2014 15:57 PM

Calling it a miraculous day, an American doctor infected with Ebola left his isolation unit and warmly hugged his docto . . .

FDA Red Tape Blocks Effective Treatments

Thursday, 21 Aug 2014 15:26 PM

Are effective new treatments being kept from American consumers because government red tape has tied the hands of FDA re . . .

Psoriasis Drug Effective in Trial

Thursday, 21 Aug 2014 12:39 PM

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved